Glenmark Pharma Q3 results: Standalone loss at Rs 20 cr, revenue dips 38.4%

Glenmark is going through a transitionary phase on account of divestment of Glenmark Life Sciences, says MD

from Latest News https://ift.tt/k6oaDld
via WebMD https://bsmedia.business-standard.com/_media/bs/img/article/2019-08/14/thumb/1565801938-3166.jpg